Recordati
Recordati, established in 1926 and headquartered in Milan, Italy, is an international pharmaceutical group dedicated to the research, development, manufacturing, and marketing of specialty pharmaceuticals. With over 3,300 employees, the company operates in various regions, including major European countries, Russia, Turkey, and the United States. Recordati's field force of more than 1,700 medical representatives promotes a diverse portfolio of innovative medications, focusing on both proprietary products and licensed therapies in areas such as cardiovascular health, urogenital disorders, and rare diseases. The company’s revenue is primarily generated from its operations in Italy, followed by the United States, France, and Germany. Recordati is known for its strategic partnerships in acquiring new product licenses and is committed to developing treatments for rare diseases alongside primary care therapies.
7 past transactions
EUSA Pharma
Acquisition in 2021
Founded in 2006, EUSA Pharma is a global specialty pharmaceutical company headquartered in the UK. It focuses on oncology and critical diseases, offering a portfolio of approved products such as Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®. The company aims to expand its portfolio through acquisitions and strategic partnerships, supported by significant funding from Essex Woodlands.
Pro Farma
Acquisition in 2016
Pro Farma is a company engaged in the sourcing and distribution of medicinal products, including both prescription and over-the-counter drugs, primarily within Switzerland. It specializes in selected therapeutic areas and also offers a variety of services for pharmaceutical companies, supporting their operations in Switzerland and internationally. Through its focused approach, Pro Farma aims to enhance the availability of essential pharmaceutical products and foster collaborations with industry partners.
Italchimici Spa
Acquisition in 2016
Italchimici Spa, along with its subsidiaries, produces and supplies raw materials.
Casen Fleet Laboratories
Acquisition in 2013
Casen Fleet Laboratories is a Madrid-based manufacturer of pharmaceutical products, focusing primarily on gastroenterology and women's health. Established in 1985, the company operates a facility in Zaragoza that spans 23,000 square meters, which has undergone significant expansions and renovations to enhance its production capabilities. The company is dedicated to developing new products, conducting clinical research, and marketing these products within its specialized areas. With a range of specialist-endorsed offerings, Casen Fleet Laboratories aims to address specific health needs while ensuring high standards of quality and innovation in its pharmaceutical solutions.
OPALIA Pharma
Acquisition in 2013
Opalia Pharma S.A. is a pharmaceutical manufacturer based in Ariana, Tunisia, specializing in the production and marketing of generic medicinal products. Founded in 1988, the company offers a diverse range of products targeting dermatology, gastrointestinal, and respiratory diseases, primarily in liquid and semi-solid forms. In addition to its manufacturing capabilities, Opalia Pharma provides various services, including development, regulatory support, and pharmaceutical release, alongside galenical and analytical development services. Its expertise encompasses the production of creams, ointments, gels, suppositories, and pessaries, catering to both external and internal medical needs. As of 2014, Opalia Pharma operates as a subsidiary of Recordati Industria Chimica e Farmaceutica S.p.A.
Farma-Projekt Sp. z o.o.
Acquisition in 2012
Farma-Projekt Sp. z o.o. produces various dietary supplements. Its products include Gastro Up, a dietary supplement for the functioning of digestive tract; Inhepax.
Orphan Europe
Acquisition in 2007
Orphan Europe SARL is a pharmaceutical company focused on the development of orphan medicinal products aimed at treating rare metabolic disorders. The company offers a portfolio that includes Cystadane, Cystagon, Normosang, and Wilzin, providing essential therapies for patients with these specific health conditions. By specializing in orphan drugs, Orphan Europe seeks to improve access to necessary treatments for individuals affected by rare diseases, thereby fulfilling a critical need in the healthcare market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.